PitchSend

argenx SE Investor Day Presentation Deck

Conclusions >30,000 IMNM, ASyS and DM patients in the U.S. Clinical evidence links IgG levels to disease activity Adaptive enrichment trial enables enrollment of broader patient population argenx Diverse panel of IgG autoantibodies emerge as key driver of muscle inflammation Efgartigimod is designed to reduce all IgGs regardless of target antigen and can further elucidate myositis biology First basket trial design based on unifying biology 37

View entire presentation